SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice

Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i’s promote a general shift to fasting state metabolism chara...

Full description

Bibliographic Details
Main Authors: Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Cardiovascular Diabetology
Subjects:
Coronary
Endothelial
Microvascular
Prediabetes
SGLT2
Online Access:http://link.springer.com/article/10.1186/s12933-019-0820-6

Internet

http://link.springer.com/article/10.1186/s12933-019-0820-6

Similar Items